In our study, we develop a novel radiomic biomarker that integrates with PDL1 expression, ECOG status, BMI, and smoking status data to enhance precision in progression-free survival prediction in 107 patients with stage 4 NSCLC treated at our institution with first-line PEMBRO monotherapy or combination therapy. The gene discussed is CD274; the disease is non-small cell lung carcinoma.